Sarepta Therapeutics to Announce First Quarter 2021 Financial Results and Recent Corporate Developments on May 5, 2021
28. April 2021 08:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2021 financial...
Sarepta Recommends Stockholders Reject the Below-Market Mini-Tender Offer by TRC Capital Investment Corporation
26. April 2021 16:05 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., April 26, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (Sarepta) (Nasdaq:SRPT) today announced that it has received notice of an unsolicited mini-tender offer by TRC Capital...
Sarepta Therapeutics Announces Fourth Year of Route 79, The Duchenne Scholarship Program
23. März 2021 08:30 ET
|
Sarepta Therapeutics, Inc.
-- Application website is now open for the 2021 Scholarship Program -- -- The Company will award up to 15 academic scholarships to individuals diagnosed with Duchenne muscular dystrophy -- ...
Sarepta Therapeutics’ Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Expression and Functional Improvements 2 Years After Administration
18. März 2021 16:31 ET
|
Sarepta Therapeutics, Inc.
-- Protein expression in muscle was sustained for two years following treatment in the low dose cohort, with mean beta-sarcoglycan expression of 54% at 24 months, compared to 36% at Day 60, as...
Sarepta Therapeutics to Present Results from its Gene Therapy and RNA Platforms at the 2021 Annual MDA Clinical and Scientific Conference
15. März 2021 08:30 ET
|
Sarepta Therapeutics, Inc.
-- Ten abstracts, including four podium presentations, reflect Sarepta’s ongoing commitment to advancing genetic medicine for rare neuromuscular disease and facilitating greater understanding of these...
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial Results and Recent Corporate Developments
01. März 2021 16:05 ET
|
Sarepta Therapeutics, Inc.
– Net product sales for the fourth quarter and full-year 2020 of $122.6 million and $455.9 million, respectively, were pre-announced in January 2021 at the J.P. Morgan Healthcare Conference – –...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
26. Februar 2021 19:12 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on Feb. 26, 2021 that...
Sarepta Therapeutics Announces FDA Approval of AMONDYS 45™ (casimersen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 45
25. Februar 2021 14:10 ET
|
Sarepta Therapeutics, Inc.
-- AMONDYS 45 is Sarepta’s third RNA exon-skipping treatment for DMD approved in the U.S. ---- Commercial distribution of AMONDYS 45 in the U.S. will commence immediately ---- Information for patients...
Sarepta Therapeutics to Present at Upcoming Investor Conferences
24. Februar 2021 16:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will...
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2020 Financial Results and Recent Corporate Developments on March 1, 2021
22. Februar 2021 08:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year...